Cidara Therapeutics (CDTX) Misses Q2 EPS by 1c

Cidara Therapeutics (NASDAQ: CDTX) reported Q2 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.61 million versus the consensus estimate of $11.55 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• SentinelOne Inc (S) PT Raised to $26 at Cantor Fitzgerald Following Strong Q2 Checks
• China semiconductor equipment imports grow 9% in July, Barclays comments